Business context and reporting period
C.H. Robinson Worldwide, Inc. filed this Form 8-K on October 5, 2026, reporting its October 4 agreement to acquire RXO, Inc. The filing concerns a proposed transaction, not quarterly or annual operating results.
Transaction terms and key financial details
- At closing, RXO would become a wholly owned C.H. Robinson subsidiary through a two-step merger. The companies expect the transaction to close in the first half of 2027.
- RXO stockholders may elect, subject to proration, either $17.25 cash plus 0.0856 C.H. Robinson share per RXO share (standard consideration), $30.25 cash, or 0.1992 C.H. Robinson share. Shares without an election receive standard consideration. Proration is intended to keep total cash and shares issued equivalent to the standard mix.
- C.H. Robinson has a commitment for a 364-day senior unsecured bridge facility of up to $4.5 billion to fund part of the cash consideration, refinance RXO’s existing credit facility, and pay related expenses. The company intends to use capital-markets transactions, new term loans and cash on hand, with bridge borrowings only as needed. The transaction is not conditional on obtaining financing.
- RXO would pay C.H. Robinson a $175 million termination fee in specified circumstances, including certain recommendation changes, competing-proposal outcomes, or specified termination followed by a qualifying alternative transaction.
- The filing provides no current revenue, profit, cash flow, margin, debt, or liquidity results for either company, and no quantified synergy estimate.
Material changes versus the prior comparable period
This is a transaction announcement rather than a periodic financial report, so it does not present comparable-period financial results. The material development is C.H. Robinson’s agreement to acquire RXO.
Outlook, conditions and risks
- Closing requires RXO stockholder approval, U.S. HSR and specified foreign antitrust clearances, an effective C.H. Robinson Form S-4 registration statement, Nasdaq listing approval for shares issued, and other customary conditions.
- The agreement may generally be terminated if the deal is not completed by July 4, 2027; the date may be extended twice by three months if only specified regulatory conditions remain outstanding.
- An RXO stockholder holding approximately 17.04% of its outstanding shares agreed to vote for the transaction, subject to stated termination and other exceptions.
- Management identifies risks including failure to obtain approvals or complete the deal, financing availability or terms, litigation, transaction costs and unknown liabilities, integration and synergy execution, disruption to employees and business relationships, and market-price changes affecting the stock component. Forward-looking statements are not guarantees.
- The filing does not quantify expected synergies, integration costs, pro forma leverage, or the effect on future earnings and cash flow. The investor presentation and forthcoming proxy statement/prospectus may provide additional details.
Important facts for investors to verify
- Review the Form S-4 and RXO proxy statement/prospectus for full terms, risks, and voting procedures when filed.
- Assess financing plans, including expected capital-markets and term-loan funding, bridge usage, and refinancing of RXO debt.
- Confirm required stockholder and regulatory approvals, closing timetable, and any amendments to the agreement.
- Evaluate the final estimated synergies, integration costs, pro forma debt and liquidity, and expected financial impact when disclosed.
- Track the C.H. Robinson share price and election proration, which affect the value and composition of consideration for RXO holders.